Table 1 Baseline characteristics of patients with diabetes (overall and in the treatment groups).
From: Real-world experience of angiotensin receptor neprilysin inhibitor on the glucose-lowering effect
ARNI (n = 200) | ACEI or ARB (n = 1355) | p-value | |
|---|---|---|---|
Age (years) | 70.0 (61.5–77.0) | 71.0 (62.0–78.0) | 0.0673 |
Sex | 0.0126 | ||
Male | 137 (68.5%) | 803 (59.3%) | |
Female | 63 (31.5%) | 552 (40.7%) | |
HbA1c (%) | 7.00 (6.60–7.85) | 6.90 (6.50–7.70) | 0.1624 |
Ejection fraction (%) | 33.9 (25–40) | 53.5 (42–67) | < 0.0001 |
Duration of DM (days) | 1125 (805–1560) | 1173 (574.5–1550.5) | 0.0672 |
Creatinine (mg/dL) | 1.10 (0.91–1.52) | 0.96 (0.78–1.26) | < 0.0001 |
eGFR (mL/min/1.73 m2) | 61.85 (44.11–79.55) | 71.45 (51.73–88.64) | 0.0001 |
Concomitant disease | |||
Hypertension | 142 (71.0%) | 1132 (83.5%) | < 0.0001 |
Dyslipidemia | 104 (52.0%) | 909 (67.1%) | < 0.0001 |
Myocardial infarction | 26 (13.0%) | 155 (11.4%) | 0.5205 |
Stroke | 12 (6.0%) | 93 (7.3%) | 0.6496 |
Atrial fibrillation | 70 (35.0%) | 309 (22.8%) | 0.0002 |
Treatment | |||
Metformin | 118 (59.0%) | 739 (54.5%) | 0.2364 |
Sulfonylurea | 73 (36.5%) | 395 (29.2%) | 0.0344 |
Thiazolidinedione | 3 (1.50%) | 136 (10.0%) | < 0.0001 |
Meglitinide or α-glucosidase inhibitors | 4 (2.0%) | 54 (4.0%) | 0.1666 |
Insulin | 59 (29.5%) | 367 (27.1%) | 0.4747 |
SGLT2 inhibitors | 46 (23.0%) | 91 (6.7%) | < 0.0001 |
GLP-1 receptor agonists | 8 (4.0%) | 1 (0.1%) | < 0.0001 |
Dipeptidyl peptidase 4 inhibitors | 108 (54.0%) | 638 (47.1%) | 0.0677 |
Statins | 169 (84.5%) | 1030 (76.0%) | 0.0077 |
Calcium channel blockers | 37 (18.5%) | 581 (42.9%) | < 0.0001 |
β-blockers | 182 (91.0%) | 930 (68.6%) | < 0.0001 |
Diuretics | 189 (94.5%) | 700 (51.7%) | < 0.0001 |
